Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients

Pharmacogenomics

Volumn 13, Issue 12, 2012, Pages 1339-1349

  Hung, Chin Chuan ^a,b   Huang, Hsiao Ching ^a   Gao, Yun Han ^a   Chang, Wei Lun ^a   Ho, Jia Ling ^a   Chiou, Mu Han ^a   Hsieh, Yow Wen ^a,b   Liou, Horng Huei ^c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

ABCB1; ABCC2; CYP2C19; CYP2C9; phenytoin; polymorphism; SCN1A

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; MULTIDRUG RESISTANCE PROTEIN 1; PHENYTOIN; SODIUM CHANNEL NAV1.1; SODIUM CHANNEL NAV1.2;

ABCB1 GENE; ABCC2 GENE; ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; CYP2C19 GENE; CYP2C9 GENE; EPILEPSY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCN1A GENE; SCN2A GENE;

ADULT; ALLELES; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; GENOTYPE; HUMANS; MALE; P-GLYCOPROTEIN; PHENYTOIN; POLYMORPHISM, GENETIC;

EID: 84866334122     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.117     Document Type: Article

References (50)

1. McCorry D, Chadwick D, Marson A. Current drug treatment of epilepsy in adults. Lancet Neurol. 3, 729-735 (2004 (Pubitemid 39535258)
2. Maguire JH. Quantitative estimation of catechol/methylcatechol pathways in human phenytoin metabolism. Epilepsia 29, 753-759 (1988 (Pubitemid 19002971)
3. Fritz S, Lindner W, Roots I, Frey BM, Kupfer A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J. Pharmacol. Exp. Ther. 241, 615-622 (1987 (Pubitemid 17111571)
4. Dickinson RG, Hooper WD, Patterson M, Eadie MJ, Maguire B. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther. Drug Monit. 7, 283-289 (1985 (Pubitemid 15228334)
5. Ramasamy K, Narayan SK, Shewade DG, Chandrasekaran A. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients. Ther. Drug Monit. 32, 762-766 (2010
6. Chaudhry AS, Urban TJ, Lamba JK et al. CYP2C9.1B promoter polymorphisms, in linkage with CYP2C19.2, affect phenytoin autoinduction of clearance and maintenance dose. J. Pharmacol. Exp. Ther. 332, 599-611 (2010
7. Rosemary J, Surendiran A, Rajan S, Shashindran CH, Adithan C. Influence of the CYP2C9 and CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Ind. J. Med. Res. 123, 665-670 (2006 (Pubitemid 44083210)
8. Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a black Beninese population. Pharmacogenet. Genomics 15, 779-786 (2005 (Pubitemid 41531727)
9. Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther. Drug Monit. 26, 534-540 (2004
10. Kerb R, Aynacioglu AS, Brockmoller J et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 1, 204-210 (2001
11. van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11, 287-291 (2001 (Pubitemid 32537401)
12. Aynacioglu AS, Brockmoller J, Bauer S et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol. 48, 409-415 (1999 (Pubitemid 29417726)
13. Cavalleri GL, McCormack M, Alhusaini S, Chaila E, Delanty N. Pharmacogenomics and epilepsy: The road ahead. Pharmacogenomics 12, 1429-1447 (2011
14. Depondt C, Shorvon SD. Genetic association studies in epilepsy pharmacogenomics: Lessons learnt and potential applications. Pharmacogenomics 7, 731-745 (2006 (Pubitemid 44219403)
15. Yaari Y, Selzer ME, Pincus JH. Phenytoin: Mechanisms of its anticonvulsant action. Ann. Neurol. 20, 171-184 (1986 (Pubitemid 16044204)
16. Woodbury DM. Phenytoin: Proposed mechanisms of anticonvulsant action. Adv. Neurol. 27, 447-471 (1980
17. Ferraro TN, Buono RJ. The relationship between the pharmacology of antiepileptic drugs and human gene variation: An overview. Epilepsy Behav. 7, 18-36 (2005 (Pubitemid 40975276)
18. Abou-Khalil B, Ge Q, Desai R et al. Partial and generalized epilepsy with febrile seizures plus and a novel SCN1A mutation. Neurology 57, 2265-2272 (2001 (Pubitemid 34016462)
19. Tate SK, Depondt C, Sisodiya SM et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA 102, 5507-5512 (2005 (Pubitemid 40530288)
20. Tate SK, Singh R, Hung CC et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet. Genomics 16, 721-726 (2006 (Pubitemid 44454866)
21. Manna I, Gambardella A, Bianchi A et al. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 52, e40-e44 (2011
22. Zimprich F, Stogmann E, Bonelli S et al. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. Epilepsia 49, 1108-1109 (2008 (Pubitemid 351794005)
23. Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br. J. Clin. Pharmacol. 66, 304-307 (2008
24. Hung CC, Chang WL, Ho JL et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics 13, 159-169 (2012
25. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br. J. Clin. Pharmacol. 68, 214-220 (2009
26. Neerati P, Ganji D, Bedada SK. Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. Eur. J. Pharm. Sci. 44, 27-31 (2011
27. van Vliet EA, van Schaik R, Edelbroek PM et al. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J. Pharmacol. Exp. Ther. 322, 141-147 (2007 (Pubitemid 46956371)
28. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52, 333-346 (2007 (Pubitemid 46123353)
29. Potschka H, Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 42, 1231-1240 (2001 (Pubitemid 33070662)
30. Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin. Pharmacokinet. 43, 553-576 (2004 (Pubitemid 38951800)
31. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 26, 180-185 (2004 (Pubitemid 38501215)
32. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97, 3473-3478 (2000 (Pubitemid 30183327)
33. Maleki M, Sayyah M, Kamgarpour F et al. Association between ABCB1-T1236C polymorphism and drug-resistant epilepsy in Iranian female patients. Iran Biomed. J. 14, 89-96 (2010
34. Kwan P, Baum L, Wong V et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav. 11, 112-117 (2007 (Pubitemid 47087203)
35. Tan NC, Heron SE, Scheffer IE et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 63, 1090-1092 (2004 (Pubitemid 39287923)
36. Siddiqui A, Kerb R, Weale ME et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348, 1442-1448 (2003 (Pubitemid 36407173)
37. Hung CC, Jen Tai J, Kao PJ, Lin MS, Liou HH. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics 8, 1151-1158 (2007
38. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 6, 411-417 (2005 (Pubitemid 40916364)
39. Begley DJ. ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 10, 1295-1312 (2004 (Pubitemid 38559749)
40. Haenisch S, Zimmermann U, Dazert E et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 7, 56-65 (2007 (Pubitemid 46322080)
41. Kim WJ, Lee JH, Yi J et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet. Genomics 20, 249-256 (2010
42. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 30, 389-399 (1989
43. Kwan P, Arzimanoglou A, Berg AT et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51, 1069-1077 (2010
44. Grover S, Gourie-Devi M, Bala K, Sharma S, Kukreti R. Genetic association analysis of transporters identifies ABCC2 loci for seizure control in women with epilepsy on first-line antiepileptic drugs. Pharmacogenet. Genomics 22, 447-465 (2012
45. Grover S, Gourie-Devi M, Baghel R et al. Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics 11, 927-941 (2010
46. Lewontin RC. The interaction of selection and linkage. II. Optimum models. Genetics 50, 757-782 (1964
47. Lewontin RC. The interaction of selection and linkage. I. General considerations; heterotic models. Genetics 49, 49-67 (1964
48. Kim MK, Moore JH, Kim JK et al. Evidence for epistatic interactions in antiepileptic drug resistance. J. Hum. Genet. 56, 71-76 (2011
49. Kelly PJ, Stallard N, Whittaker JC. Statistical design and analysis of pharmacogenetic trials. Stat. Med. 24, 1495-1508 (2005 (Pubitemid 40716349)
50. Heinzen EL, Yoon W, Tate SK et al. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am. J. Hum. Genet. 80, 876-883 (2007 (Pubitemid 46668456)